X4 Pharmaceuticals (XFOR) Enterprise Value (2017 - 2025)

X4 Pharmaceuticals has reported Enterprise Value for 9 years, with the latest figure at -$217.0 million in Q4 2025.

• For the quarter ending Q4 2025, Enterprise Value fell 289.68% year-over-year to -$217.0 million; the trailing twelve-month figure through Dec 2025 stood at -$217.0 million (down 289.68% YoY), and the FY2025 full-year result was -$217.0 million, down 289.68% from the prior year.
• Enterprise Value for Q4 2025 stood at -$217.0 million, down from -$69.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$39.2 million in Q2 2025, with the low at -$217.0 million in Q4 2025.
• Historically, Enterprise Value has averaged -$93.6 million across 5 years, with a median of -$87.6 million in 2021.
• The largest YoY upside for Enterprise Value was 73.36% in 2025 against a maximum downside of 289.68% in 2025.
• X4 Pharmaceuticals' Enterprise Value stood at -$81.8 million in 2021, then tumbled by 48.82% to -$121.7 million in 2022, then climbed by 18.49% to -$99.2 million in 2023, then soared by 43.86% to -$55.7 million in 2024, then tumbled by 289.68% to -$217.0 million in 2025.
• The last three Enterprise Value figures came in at -$217.0 million (Q4 2025), -$69.6 million (Q3 2025), and -$39.2 million (Q2 2025), per Business Quant data.